Listen
SAMSCA (tolvaptan), vasopressin antagonist
NEPHROLOGY - UPDATE
Opinions on drugs -
Posted on
Dec 18 2018
Reason for request
Inclusion
High clinical benefit in hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion, but no clinical improvement in the therapeutic strategy.
SAMSCA has MA for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Its efficacy has been demonstrated versus placebo only in terms of blood sodium correction, but not on clinically relevant criteria such as hyponatraemia complications, quality of life, duration of hospitalisation or mortality.
Overly rapid correction of hyponatraemia with tolvaptan should be avoided.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
-
